MannKind Corp (MNKD)

0.62
0.02 3.63
NASDAQ : Health Care
Prev Close 0.60
Open 0.58
Day Low/High 0.57 / 0.63
52 Wk Low/High 0.64 / 5.37
Volume 3.93M
Avg Volume 3.26M
Exchange NASDAQ
Shares Outstanding 478.05M
Market Cap 291.61M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

MNKD: Insiders vs. Shorts

MNKD: Insiders vs. Shorts

The most recent short interest data was recently released for the 07/29/2016 settlement date, and MannKind Corp is one of the most shorted stocks of the Russell 3000, based on 46.40 "days to cover" versus the median component at 6.42. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

MannKind Corporation Reports 2016 Second Quarter Financial Results

MannKind Corporation Reports 2016 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

What to Expect from MannKind's (MNKD) Q2 Earnings Report

What to Expect from MannKind's (MNKD) Q2 Earnings Report

MannKind (MNKD) is set to report 2016 second quarter results after Monday's market close.

Mannkind Assumes Responsibility For Distribution Of Afrezza® And Launches Patient Reimbursement And Adherence Support Programs

Mannkind Assumes Responsibility For Distribution Of Afrezza® And Launches Patient Reimbursement And Adherence Support Programs

Frank Pompilio, PharmD, joins as Vice President, North America Medical Affairs

Commit To Purchase MannKind Corp At $0.50, Earn 24% Using Options

Commit To Purchase MannKind Corp At $0.50, Earn 24% Using Options

Investors considering a purchase of MannKind Corp shares, but tentative about paying the going market price of $0.9858/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $0.50 strike, which has a bid at the time of this writing of 12 cents.

Here's Why MannKind (MNKD) Stock Is Down Today

Here's Why MannKind (MNKD) Stock Is Down Today

MannKind (MNKD) stock is plummeting in late-morning trading on Tuesday after reporting 2016 first quarter results.

MannKind Corporation Reports 2016 First Quarter Financial Results

MannKind Corporation Reports 2016 First Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.

First Week of June 17th Options Trading For MannKind (MNKD)

First Week of June 17th Options Trading For MannKind (MNKD)

Investors in MannKind Corp saw new options begin trading this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new June 17th contracts and identified one put and one call contract of particular interest.

Notable Thursday Option Activity: MNKD, ONVO, IRBT

Notable Thursday Option Activity: MNKD, ONVO, IRBT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MannKind Corp , where a total of 45,300 contracts have traded so far, representing approximately 4.5 million underlying shares. That amounts to about 46.9% of MNKD's average daily trading volume over the past month of 9.7 million shares.

MannKind To Discuss U.S. Commercialization Update For Afrezza®

MannKind To Discuss U.S. Commercialization Update For Afrezza®

- Analyst Call Scheduled for April 19, 2016 at 5:00 PM EDT -

MannKind Regains Afrezza® Marketing Rights

MannKind Regains Afrezza® Marketing Rights

Transition Ensures Innovative Inhalable Insulin Will Continue to be Available to Adults with Diabetes

Commit To Buy MannKind Corp At $1, Earn 50.4% Annualized Using Options

Commit To Buy MannKind Corp At $1, Earn 50.4% Annualized Using Options

Investors eyeing a purchase of MannKind Corp stock, but tentative about paying the going market price of $2.15/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $1 strike, which has a bid at the time of this writing of 42 cents.

MannKind (MNKD) Stock Drops on Q4 Loss

MannKind (MNKD) Stock Drops on Q4 Loss

MannKind (MNKD) stock is sinking in mid-morning trading on Tuesday after the biopharmaceutical company reported a wider-than-expected loss during the 2015 fourth quarter.

MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings

MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings

MannKind (MNKD) stock is declining in after-hours trading on Monday after reporting its 2015 fourth quarter financial results.